{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:31Z","timestamp":1790351431662,"version":"4.1.0"},"update-to":[{"DOI":"10.12688\/f1000research.74570.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000}}],"reference-count":73,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm generated by reciprocal chromosomal translocation, t (9; 22) (q34; q11) in the transformed hematopoietic stem cell. Tyrosine kinase inhibitors (TKIs) target the mature proliferating BCR-ABL cells, the major CML driver, and increase overall and disease-free survival. However, mutant clones, pre-existing or due to therapy, develop resistance against TKIs. BCR-ABL1 oncoprotein activates various molecular pathways including the RAS\/RAF\/MEK\/ERK pathway, JAK2\/STAT pathway, and PI3K\/AKT\/mTOR pathway. Stimulation of these pathways in TKI resistant CML patients, make them a new target. Moreover, a small proportion of CML cells, leukemic stem cells (LSCs), persist during the TKI therapy and sustain the disease in the patient. Engraftment of LSCs in the bone marrow niche and dysregulation of miRNA participate greatly in the TKI resistance. Current efforts are needed for determining the reason behind TKI resistance, identification, and elimination of CML LSC might be of great need for cancer cure.<\/ns4:p>","DOI":"10.12688\/f1000research.74570.2","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T13:25:06Z","timestamp":1644413106000},"page":"1288","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review"],"prefix":"10.12688","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-9467","authenticated-orcid":false,"given":"Mohammad","family":"Al Hamad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"133-143","DOI":"10.1016\/S1535-6108(02)00032-6","article-title":"Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.","volume":"1","author":"E Yeoh","year":"2002","journal-title":"Cancer Cell."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1823-1833","DOI":"10.1038\/leu.2010.159","article-title":"Insights into the stem cells of chronic myeloid leukemia.","volume":"24","author":"I Sloma","year":"2010","journal-title":"Leukemia."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"441-453","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer.","volume":"7","author":"J Melo","year":"2007","journal-title":"Nat. Rev. Cancer."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2563-2572","DOI":"10.1182\/blood-2007-10-116186","article-title":"Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.","volume":"111","author":"V Pullarkat","year":"2008","journal-title":"Blood."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"926-935","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).","volume":"109","author":"K Schultz","year":"2007","journal-title":"Blood."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1399-1412","DOI":"10.1084\/jem.189.9.1399","article-title":"The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.","volume":"189","author":"S Li","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1362-1367","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.","volume":"94","author":"C Lucas","year":"2009","journal-title":"Haematologica."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"164-172","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia.","volume":"341","author":"S Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"237-245","DOI":"10.1002\/gcc.2870080406","article-title":"Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia.","volume":"8","author":"A Hagemeijer","year":"1993","journal-title":"Genes Chromosomes Cancer."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"963-981","DOI":"10.1016\/S0950-3536(87)80034-3","article-title":"Chromosome abnormalities in CML.","volume":"1","author":"A Hagemeijer","year":"1987","journal-title":"Baillieres Clin. Haematol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"290-293","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"J Rowley","year":"1973","journal-title":"Nature."},{"key":"ref12","first-page":"990-998","article-title":"The molecular genetics of Philadelphia chromosome-positive leukemias.","volume":"319","author":"R Kurzrock","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"319-325","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"S Graham","year":"2002","journal-title":"Blood."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"219-222","DOI":"10.1038\/leu.2009.190","article-title":"Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.","volume":"24","author":"S Mustjoki","year":"2010","journal-title":"Leukemia."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"840-853","DOI":"10.1128\/MCB.21.3.840-853.2001","article-title":"The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.","volume":"21","author":"X Zhang","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2744-2752","DOI":"10.1002\/ijc.23467","article-title":"Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR\/ABL.","volume":"122","author":"T Beissert","year":"2008","journal-title":"Int. J. Cancer."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"7045-7053","DOI":"10.1158\/0008-5472.CAN-06-4312","article-title":"BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.","volume":"67","author":"S Chu","year":"2007","journal-title":"Cancer Res."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1080-1089","DOI":"10.1038\/leu.2012.351","article-title":"Contributions of the RhoGEF activity of p210 BCR\/ABL to disease progression.","volume":"27","author":"I Tala","year":"2013","journal-title":"Leukemia."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"280-282","DOI":"10.1038\/ng0398-280","article-title":"An intramolecular SH3-domain interaction regulates c-Abl activity.","volume":"18","author":"D Barila","year":"1998","journal-title":"Nat. Genet."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1938-1942","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.","volume":"289","author":"T Schindler","year":"2000","journal-title":"Science."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.","volume":"17","author":"S Soverini","year":"2018","journal-title":"Mol. Cancer."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"859-871","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase.","volume":"112","author":"B Nagar","year":"2003","journal-title":"Cell."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"4-10","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene.","volume":"40","author":"M Sattler","year":"2003","journal-title":"Semin. Hematol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"175-185","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.","volume":"75","author":"A Pendergast","year":"1993","journal-title":"Cell."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"27-37","DOI":"10.1016\/S1097-2765(03)00274-0","article-title":"Autoinhibition of Bcr-Abl through its SH3 domain.","volume":"12","author":"K Smith","year":"2003","journal-title":"Mol. Cell."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2167-2175","DOI":"10.1182\/blood-2013-02-485573","article-title":"JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.","volume":"122","author":"W Warsch","year":"2013","journal-title":"Blood."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1447-1459","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia.","volume":"385","author":"J Apperley","year":"2015","journal-title":"Lancet."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143587","article-title":"DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model.","volume":"13","author":"B Lebecque","year":"2021","journal-title":"Cancers (Basel)."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1255-1268","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.","volume":"34","author":"X An","year":"2010","journal-title":"Leuk. Res."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"994-1004","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"S O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"501-506","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.","volume":"463","author":"J Zhang","year":"2010","journal-title":"Nature."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1648-1671","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.","volume":"30","author":"J Steegmann","year":"2016","journal-title":"Leukemia."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.","volume":"6","author":"L Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"5790-5797","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.","volume":"66","author":"J Tokarski","year":"2006","journal-title":"Cancer Res."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"276-283","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.","volume":"102","author":"S Branford","year":"2003","journal-title":"Blood."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"28-37","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"T Hughes","year":"2006","journal-title":"Blood."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"122-131","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.","volume":"16","author":"A Quintas-Cardama","year":"2009","journal-title":"Cancer Control."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"129-141","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.","volume":"7","author":"E Weisberg","year":"2005","journal-title":"Cancer Cell."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"4204-4210","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.","volume":"27","author":"T Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1783-1796","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.","volume":"369","author":"J Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"655-665","DOI":"10.2217\/14796694.2.6.655","article-title":"Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.","volume":"2","author":"A Quintas-Cardama","year":"2006","journal-title":"Future Oncol."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"469-471","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants.","volume":"27","author":"S Redaelli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"401-412","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.","volume":"16","author":"T O'Hare","year":"2009","journal-title":"Cancer Cell."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"393-404","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.","volume":"132","author":"J Cortes","year":"2018","journal-title":"Blood."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"847-856","DOI":"10.2174\/1568009617666171002142659","article-title":"Ponatinib: A Review of Efficacy and Safety.","volume":"18","author":"F Massaro","year":"2018","journal-title":"Curr. Cancer Drug Targets."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2315-2326","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.","volume":"381","author":"T Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"106337","DOI":"10.1016\/j.leukres.2020.106337","article-title":"Novel therapeutic approaches in chronic myeloid leukemia.","volume":"91","author":"N Ozgur Yurttas","year":"2020","journal-title":"Leuk. Res."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1774-1782","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development.","volume":"19","author":"A Burchert","year":"2005","journal-title":"Leukemia."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"715-727","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.","volume":"20","author":"L Packer","year":"2011","journal-title":"Cancer Cell."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1115-1126","DOI":"10.2147\/DDDT.S132092","article-title":"Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.","volume":"11","author":"P Xin","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia.","volume":"9","author":"F Loscocco","year":"2019","journal-title":"Front. Oncol."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"692-702","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.","volume":"23","author":"A Giustacchini","year":"2017","journal-title":"Nat. Med."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"435-441","DOI":"10.1038\/sj.leu.2403649","article-title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease.","volume":"19","author":"W Eisterer","year":"2005","journal-title":"Leukemia."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"219-226","DOI":"10.3324\/haematol.2010.035006","article-title":"CD34(+)\/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin.","volume":"97","author":"H Herrmann","year":"2012","journal-title":"Haematologica."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"5118-5132","DOI":"10.1182\/bloodadvances.2020001742","article-title":"Delineation of target expression profiles in CD34+\/CD38- and CD34+\/CD38+ stem and progenitor cells in AML and CML.","volume":"4","author":"H Herrmann","year":"2020","journal-title":"Blood Adv."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"609-621","DOI":"10.2147\/OTT.S255299","article-title":"Identification and Targeting of Thomsen-Friedenreich and IL1RAP Antigens on Chronic Myeloid Leukemia Stem Cells Using Bi-Specific Antibodies.","volume":"14","author":"R Eldesouki","year":"2021","journal-title":"Onco. Targets. Ther."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fonc.2018.00194","article-title":"Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.","volume":"8","author":"M Bocchia","year":"2018","journal-title":"Front. Oncol."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"136-147","DOI":"10.3324\/haematol.2018.212365","article-title":"The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL\/TAL1 - CD44 axis.","volume":"105","author":"P Godavarthy","year":"2020","journal-title":"Haematologica."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"3767-3777","DOI":"10.1182\/blood-2013-05-501460","article-title":"Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression.","volume":"122","author":"B Laperrousaz","year":"2013","journal-title":"Blood."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"2860-2871","DOI":"10.1182\/blood-2017-08-801019","article-title":"Immature CML cells implement a BMP autocrine loop to escape TKI treatment.","volume":"130","author":"E Grockowiak","year":"2017","journal-title":"Blood."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"799-811","DOI":"10.1016\/j.stem.2012.09.001","article-title":"Attenuation of miR-126 activity expands HSC in vivo without exhaustion.","volume":"11","author":"E Lechman","year":"2012","journal-title":"Cell Stem Cell."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"450-462","DOI":"10.1038\/nm.4499","article-title":"Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.","volume":"24","author":"B Zhang","year":"2018","journal-title":"Nat. Med."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"8468-8475","DOI":"10.26355\/eurrev_201910_19159","article-title":"MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia.","volume":"23","author":"Y Liu","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref64","doi-asserted-by":"crossref","first-page":"612573","DOI":"10.3389\/fphar.2020.612573","article-title":"miRNome profiling of LSC-enriched CD34(+)CD38(-)CD26(+) fraction in Ph(+) CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool.","volume":"11","author":"M Ruiz","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"177-191","DOI":"10.1016\/j.stem.2016.05.004","article-title":"ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.","volume":"19","author":"M Zipeto","year":"2016","journal-title":"Cell Stem Cell."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12943-016-0518-2","article-title":"Clinical significance of microRNAs in chronic and acute human leukemia.","volume":"15","author":"C Yeh","year":"2016","journal-title":"Mol. Cancer."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"395-402","DOI":"10.3892\/br.2016.747","article-title":"Emerging role of microRNA-21 in cancer.","volume":"5","author":"Y Feng","year":"2016","journal-title":"Biomed Rep."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"9666","DOI":"10.1038\/s41598-019-46132-9","article-title":"MicroRNA signature refine response prediction in CML.","volume":"9","author":"R Alves","year":"2019","journal-title":"Sci. Rep."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1117-1124","DOI":"10.1016\/j.leukres.2015.07.008","article-title":"Silencing of miR-21 sensitizes CML CD34+ stem\/progenitor cells to imatinib-induced apoptosis by blocking PI3K\/AKT pathway.","volume":"39","author":"W Wang","year":"2015","journal-title":"Leuk. Res."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1532-1544","DOI":"10.1182\/blood-2017-05-783845","article-title":"hsa-mir183\/EGR1-mediated regulation of E2F1 is required for CML stem\/progenitor cell survival.","volume":"131","author":"F Pellicano","year":"2018","journal-title":"Blood."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"349-356","DOI":"10.1016\/j.leukres.2012.12.003","article-title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.","volume":"37","author":"Y Liu","year":"2013","journal-title":"Leuk. Res."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1752-1760","DOI":"10.1038\/leu.2012.65","article-title":"Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.","volume":"26","author":"Y Yu","year":"2012","journal-title":"Leukemia."},{"key":"ref73","doi-asserted-by":"publisher","first-page":"49451-49469","DOI":"10.18632\/oncotarget.17706","article-title":"Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.","volume":"8","author":"S Salati","year":"2017","journal-title":"Oncotarget."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/10-1288\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/10-1288\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/10-1288\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T11:35:29Z","timestamp":1646048129000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/10-1288\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":73,"URL":"https:\/\/doi.org\/10.12688\/f1000research.74570.2","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.120985.r123029","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.120985.r125621","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.120985.r123029","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.120985.r125621","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/10-1288\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.120985.r123029, Ala-Eddin Al Moustafa, College of Medicine, QU Health, Qatar University, Doha, Qatar, 23 Feb 2022, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/10-1288\/v2#referee-response-123029","order":0,"name":"referee-response-123029","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.120985.r125621, Pinar Arslan, Biology Department, Faculty of Science, \u00c7ank\u0131r\u0131 Karatekin University, \u00c7ank\u0131r\u0131, Turkey, 28 Feb 2022, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/10-1288\/v2#referee-response-125621","order":1,"name":"referee-response-125621","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}